Neurocrine Biosciences Q3 Adjusted EPS $1.54 Beats $0.98 Estimate, Sales $498.80M Beat $469.92M Estimate
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences reported Q3 earnings of $1.54 per share, beating the analyst consensus estimate of $0.98 by 57.14%. The company also reported quarterly sales of $498.80 million, surpassing the analyst consensus estimate of $469.92 million by 6.15%. Both earnings and sales have increased compared to the same period last year.
October 31, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences reported better than expected Q3 earnings and sales, which could positively impact the stock.
Neurocrine Biosciences reported Q3 earnings and sales that beat analyst estimates, which is typically a positive signal for the stock. The company's earnings per share increased by 57.14% and sales increased by 6.15% compared to estimates, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100